Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Magnosco - NOAH18 Berlin


Published on

Company Pitch by Inga Bergen, Magnosco at the Axel Springer NOAH Conference 2018 in Berlin, Tempodrom 6-7 June 2018.

Published in: Healthcare
  • How I Cured My Uterine Fibroids? Reverse And Eliminate Uterine Fibroids, Safe & Natural With Fast Results.. ♣♣♣
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

Magnosco - NOAH18 Berlin

  1. 1. NOAH BERLIN Berlin, 27.5.2018 1
  2. 2. Three Conferences, One Mission: Empower the European Digital Ecosystem To provide a physical marketplace that facilitates funding of digital European companies at all stages Mission MissionMission To promote Israel - European relationships and enable funding To bring together future-shaping executives and investors active across segments driven by digital revolution Connecting Capital with Entrepreneurs Connecting European Champions and Challengers Connecting Israel’s Startups with Large Corporates and Investors 30-31 October 2018 Old Billingsgate, London 13-14 June 2019 STATION Berlin 9-10 April 2019 Haoman 17, Tel Aviv
  3. 3. Skin cancer is the fastest growing type of cancer worldwide Magnosco NOAH Presentation Every 54 minutes one person dies of melanoma. 22.000 European citizens lose their lives to the disease. 440.000 suspicious lesions are excised in Germany each year. 227.05.18
  4. 4. Addressable market is worth € 2.9 bn •  Annual cost of treating skin cancer estimated at $ 8.1 bn in the US alone •  Melanoma market annual growth by 6-12% 3Magnosco NOAH Presentation . 27.05.1827.05.18
  5. 5. The problem: skin cancer screening is time-consuming and biopsi-heavy 4Magnosco NOAH Presentation Result after ~14 days Identification Biopsie Histological findings of the skin sample Only in 1-3 % confirmed. * Source: publication/ 5663596_Melanoma_diagnosis_Austral ian_dermatologists%27_number_need ed_to_treat *Helfand M. et al: Screening for skin cancer. Am J Prev Med. 20, 47-58 (2001) 27.05.18
  6. 6. The solution: magnosco DermaFC non- invasive melanoma diagnostics *as of Q4 2018 1-5 minutes.* Doctor identifies suspicious lesions Diagnosis (recommendation) Scanning with DermaFC 27.05.18 Magnosco NOAH Presentation 5
  7. 7. Magnosco‘s patented method: Dermatofluoroscopy 6Magnosco NOAH Presentation Laser Spectroscopy Artificial Intelligence research & science partners 27.05.18
  8. 8. The CE-certified medical product makes malignant cells visible 7Magnosco NOAH Presentation Melanoma Healthy Tissue 27.05.18 objective, physical method * early detection * immediate visual result & score
  9. 9. Go-to-market in Germany: 130 Mio € spent on skin cancer screening 8Magnosco NOAH Presentation skin cancer screening qualified physicians Potential market Source_ Zentrum für Krebsregisterdaten *2016 in Germany/ Bundesärztekammer 27.05.18
  10. 10. Adressing KOLs with installation fee & payPerUse 9 Calculation of customer benefits/ additional revenue for doctors Revenue for Clinics up to 250k € per year Examinations with DermaFC per month Price per examination licence for magnosco Income clinic month Share magnosco/ month 300 98,7 € 29,7 € 20.700,0 € 8.910,0 € 200 98,7 € 29,7 € 13.800,0 € 5.940,0 € 100 98,7 € 29,7 € 6.900,0 € 2.970,0 € 50 98,7 € 29,7 € 3.450,0 € 1.485,0 € •  Class 2A medical device approved for diagnostic support of malignant melanoma •  Use in suspected melanoma, alternative to excision •  Billing via fee regulations doctors or as a self-payer payment (“IGEL-Leistung”) 27.05.18 Magnosco NOAH Presentation
  11. 11. Trusted customers and partners 1027.05.18 Magnosco NOAH Presentation u  Key opinion leaders at Germany’s leading dermatology clinics u  Manufacturing Partners u  Software Developmemt Partner u  AOK-Nordost u  Research & Science Partners u  Regulatory affairs partner Customers (prospect) Partners u  User Experience/ Usability Partner u  PR Partner
  12. 12. Outlook: Further development in 2019 1127.05.18 Magnosco NOAH Presentation magnosco screening App in vivo DermaFC 2.0 ex vivo HistoFC
  13. 13. Outlook: No1 partner for skin cancer screening 1227.05.18 Magnosco NOAH Presentation HistoFC •  ex-vivo •  diagnostics for labratories self documenting lesions DermaFC App (patient) DermaFC App (clinic) documenting lesions in high resolution over longer periods DermaFC 2.0 •  small hand-device in-vivo SCS Creating awareness, patient acquisition & retention Info-channels Patient Clinic
  14. 14. Team experienced in building successful companies & medical device sales 1321.05.18 Magnosco NOAH Presentation27.05.18
  15. 15. Investment Facts •  Funding received 5,5 Million € •  Volume: 10 Million € •  Duration: 2-3 years •  Structure: German GmbH Use of proceeds: Go-to-market, new product development 1427.05.18 Magnosco NOAH Presentation
  16. 16. Inga Bergen Tel: +49 171 1030155 FEATURED IN MagnoscoGmbH SIENTIFIC PARTNERS
  17. 17. Selected Completed NOAH Transactions Focus on Leading European Internet companies Covering over 400 companies across 25 online verticals, a broad range of over 500 investors as well as 100+ online-focused corporates Deep understanding of industry dynamics Ability to add value beyond banking advice Facilitates overall process and minimizes management distraction NOAH Advisors is globally well connected and has direct access to virtually all key players in the industry Knowledge of and strong relationships with potential buyers’ key decision makers Proactively finds and unlocks attractive investment opportunities for leading investors Annual NOAH Conference in its 8th year Over 40 years of combined relevant M&A experience Routine execution of M&A and financing transactions with sizes of several billion euros 30 successfully completed NOAH Advisors transactions underline successful transfer of M&A competencies to the Internet sector Entrepreneurial mind-set, focused on growing the business and establishing a reputation for excellence Ability to deliver top results in short time frames Highly success-based compensation structures align interests of clients and NOAH Advisors, and demonstrate conviction to deliver top results Creative deal solutions December 2014 September 2014 October 2014 May 2014 Sale of 100% of for $800m to Exclusive Financial Advisor to Fotolia and the Selling Shareholders Sale of 100% of for €80m to Exclusive Financial Advisor to Trovit and its Shareholders Sale of controlling stake in to Exclusive Financial Advisor to and its Shareholders sold 100% of for $228m to a joint venture between Exclusive Financial Advisor to Yad2 and its Shareholders Unique Industry Know-How Unmatched Network and Relationships Strong Investment Banking Competence Full Commitment - We Are Entrepreneurs! EUROPE’S LEADING INTERNET CORPORATE FINANCE BOUTIQUE September 2016October 2016 December 2016 Financial Advisor to Oakley Capital ® Marco Rodzynek Managing Director & Founder Jan Brandes Managing Director The NOAH Advisors Core Banking Team Acquisition of a Majority Stake in by from at a valuation of €300m Investment in Exclusive Financial Advisor to KäuferPortal and its Shareholders by 84% Ownership Financial Advisor to Silver Lake Investment in by August 2017 Financial Advisor to EMK Capital Acquisition of a Majority Stake in by at a valuation of $200m Aleksander Skwarczek Analyst Nikhil Parmar Director